197 related articles for article (PubMed ID: 16464264)
1. Identifying barriers to participation in prophylactic HIV-1 vaccine trials.
Peters BS
Int J STD AIDS; 2006 Feb; 17(2):73. PubMed ID: 16464264
[No Abstract] [Full Text] [Related]
2. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
[TBL] [Abstract][Full Text] [Related]
3. [AIDS vaccine: who should be selected for the test?].
Marcus U
Fortschr Med; 1995 Nov; 113(32):16-7. PubMed ID: 8543269
[No Abstract] [Full Text] [Related]
4. Who will enroll? Predicting participation in a phase II AIDS vaccine trial.
Halpern SD; Metzger DS; Berlin JA; Ubel PA
J Acquir Immune Defic Syndr; 2001 Jul; 27(3):281-8. PubMed ID: 11464149
[TBL] [Abstract][Full Text] [Related]
5. IAVI begins trials of AIDS vaccine.
Expert Rev Vaccines; 2003 Dec; 2(6):731. PubMed ID: 15282843
[No Abstract] [Full Text] [Related]
6. Steady but slow progress toward AIDS vaccine.
Minn Med; 1993 Aug; 76(8):38-9. PubMed ID: 8371702
[No Abstract] [Full Text] [Related]
7. Tepid endorsement for HIV vaccine trial.
Science; 1995 Feb; 267(5200):966. PubMed ID: 7863340
[No Abstract] [Full Text] [Related]
8. Correlates of HIV vaccine trial participation: an Indian perspective.
Sahay S; Mehendale S; Sane S; Brahme R; Brown A; Charron K; Beyrer C; Bollinger R; Paranjape R
Vaccine; 2005 Feb; 23(11):1351-8. PubMed ID: 15661383
[TBL] [Abstract][Full Text] [Related]
9. An HIV vaccine: breaking the paradigms.
Fauci AS
Proc Assoc Am Physicians; 1996 Jan; 108(1):6-13. PubMed ID: 8834058
[No Abstract] [Full Text] [Related]
10. AIDS/HIV. A STEP into darkness or light?
Moore JP; Klasse PJ; Dolan MJ; Ahuja SK
Science; 2008 May; 320(5877):753-5. PubMed ID: 18467578
[No Abstract] [Full Text] [Related]
11. Participation in HIV vaccine trials: listening to participant & community concerns.
Mills EJ; Jha P
Indian J Med Res; 2006 Dec; 124(6):608-10. PubMed ID: 17287546
[No Abstract] [Full Text] [Related]
12. [AIDS vaccine].
Sikorska EJ
Pneumonol Alergol Pol; 1991; 59(3-4):146-52. PubMed ID: 1843911
[No Abstract] [Full Text] [Related]
13. Merck's HIV vaccine flop brings vectors under closer scrutiny.
Ledford H
Nat Biotechnol; 2008 Jan; 26(1):3-4. PubMed ID: 18182999
[No Abstract] [Full Text] [Related]
14. So far so good for HIV vaccine.
CMAJ; 1997 Jun; 156(12):1692. PubMed ID: 9220914
[No Abstract] [Full Text] [Related]
15. Salk group testing killed-virus AIDS vaccine.
Minn Med; 1994 Jul; 77(7):55. PubMed ID: 8052210
[No Abstract] [Full Text] [Related]
16. India targets local HIV strain in test of AIDS vaccine.
Jayaraman KS
Nature; 2004 Jan; 427(6971):185. PubMed ID: 14724601
[No Abstract] [Full Text] [Related]
17. AIDSVAX fails to prove efficacious in large-scale trial.
Expert Rev Vaccines; 2003 Dec; 2(6):731. PubMed ID: 14711356
[No Abstract] [Full Text] [Related]
18. Introduction: Back to basics: mucosal immunity and novel HIV vaccine concepts.
Broliden K; Haase AT; Ahuja SK; Shearer GM; Andersson J
J Intern Med; 2009 Jan; 265(1):5-17. PubMed ID: 19093956
[No Abstract] [Full Text] [Related]
19. How should the potency of HIV vaccine candidates be determined?
Sheets R; Bean P
Am Clin Lab; 2000; 19(8):23. PubMed ID: 11146989
[No Abstract] [Full Text] [Related]
20. 'Money down the drain' fears for AIDS vaccine trials.
Nature; 2003 Nov; 426(6964):220-1. PubMed ID: 14628016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
